Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW

Agalsidase Beta for Injection.

Drug Name]:
Agalsidase β for injection
[Approval No.]:
The active ingredient is agalsidase β. Chemical name: recombinant human α-galactosidase A, referred to as rhαGAL. Molecular formula (based on amino acid sequence): C2029H3080N5440587S27 Agalsidase β is a recombinant human α-galactosidase A, and its amino acid sequence is the same as the natural enzyme. Purified agalsidase β is a homodimeric glycoprotein with a molecular weight of about 100kD. The mature protein consists of 2 subunits of 398 amino acids (about 51kD), each of which contains 3 N-linked glycosylation sites. Excipients: mannitol, sodium dihydrogen phosphate monohydrate, sodium dihydrogen phosphate heptahydrate.
White or off-white freeze-dried block or powder.
This product should be used under the supervision of a physician who has experience in managing patients with Fabry disease or other inherited metabolic diseases.


The recommended dose of this product is 1 mg/kg, administered by intravenous infusion once every 2 weeks.

The initial infusion rate should not exceed 0.25 mg/min (15 mg/hr) to minimize the occurrence of infusion-related reactions….
Because agalsidase beta (r-hagal) is a recombinant protein, IgG antibodies are expected to appear in patients with low or no residual enzyme activity. Most patients generally develop IgG antibodies to r-haGAL within 3 months after the first infusion of agalsidase beta for injection. Over time, most serum reactions in clinical trials….


Featured products

Laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor.